非霍奇金淋巴瘤新型药物及新型疗法研究现状(3)
[6] Wang ML，M.D，Rule S，et al.Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma[J].N Engl J Med，2013，369(6)：507-516.[7] Wilson WH，Gerecitano JF，Goy A，et al.The Bruton’s Tyrosine Kinase (BTK) Inhibitor，Ibrutinib (PCI-32765)，Has Preferential Activity in the ABC Subtype of Relapsed/Refractory De Novo Diffuse Large B-Cell Lymphoma (DLBCL)：Interim Results of a Multicenter ......
您现在查看是摘要页，全文长 2689 字符。